Seattle Genetics' "Growth Is Tracking Well"

Seattle Genetics (NASDAQ:SGEN) continued its solid year-over-year increases in revenue as the biotech takes advantage of recent approvals that expanded the use of Adcetris into frontline Hodgkin lymphoma and peripheral T-cell lymphoma.